1.87

0.00% 0.00

Skye Bioscience Inc (SKYE)

Overview News Price History Discussions Forecast

Skye Bioscience Inc stock is traded at $1.87, with a volume of 66,044. It is up +0.00% in the last 24 hours and up +30.31% over the past month. Skye Bioscience Inc is a pre-clinical pharmaceutical company located in San Diego, California. The company's clinical assets focus on the modulation of cannabinoid receptor 1 ("CB1") to provide novel treatments and alternatives for diseases caused by metabolic disorders, inflammation, fibrosis, and neurodegeneration, such as obesity and glaucoma. The company's Phase 2 clinical candidates include nimacimab, a negative allosteric modulating antibody that inhibits peripheral CB1 receptors, currently being developed for the treatment of obesity and SBI-100 Ophthalmic Emulsion ("SBI-100 OE"), a CB1 agonist (activator), currently being developed for the treatment of glaucoma and ocular hypertension.

Previous Close:

$1.87

Open:

$1.87

24h Volume:

66,044

Relative Volume:

0.10

Market Cap:

$63.20M

Revenue:

Net Income/Loss:

$-21.24M

P/E Ratio:

-2.2318

EPS:

-0.8379

Net Cash Flow:

$-22.47M

1W Performance:

-8.78%

1M Performance:

+30.31%

6M Performance:

-56.91%

1Y Performance:

-84.48%

1-Day Range:

$1.87

$2.06

1-Week Range:

$1.78

$2.0998

52-Week Range:

$1.14

$12.77

Skye Bioscience Inc Stock (SKYE) Company Profile

Name

Skye Bioscience Inc

Sector

Healthcare (1172)

Industry

Biotechnology (671)

Phone

(858) 410-0266

Address

11250 EL CAMINO REAL, SUITE 100, SAN DIEGO

Employee

Twitter

Next Earnings Date

2024-11-07

Latest SEC Filings

SKYE's Discussions on Twitter

Compare SKYE with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
SKYE Skye Bioscience Inc.	3.10	12.89M	0	0	0	0.00
GOODO Gladstone Commercial Corporation	20.82	372.90M	0	0	0	0.00
JUNE Dhandho Junoon Etf	10.89	225.81M	0	0	0	0.00
SHMD Schmid Group N V	2.93	138.75M	0	0	0	0.00
PSNYW Polestar Automotive Holding Uk	0.165	327.74M	2.07B	-1.42B	-1.37B	-0.6765
MOBBW Mobilicom Limited Warrants	0.3476	352.23M	0	0	0	0.00

Skye Bioscience Inc Stock (SKYE) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Feb-28-25	Initiated	William Blair	Outperform
Sep-30-24	Initiated	Scotiabank	Sector Outperform
Sep-10-24	Initiated	JMP Securities	Mkt Outperform
Jul-09-24	Initiated	Craig Hallum	Buy
May-23-24	Initiated	Cantor Fitzgerald	Overweight
Apr-12-24	Initiated	Oppenheimer	Outperform

View All

Skye Bioscience Inc Stock (SKYE) Latest News

06:21 AM

Arecor shares jump 10% on obesity drug partnership with Skye Bioscience - Proactive Investors

06:21 AM

05:28 AM

Arecor partners with Skye Bioscience to improve formulation of obesity drug - Proactive Investors

05:28 AM

05:15 AM

Skye Bioscience Establishes Partnership with Arecor Therapeutics to Develop Enhanced Formulation of Obesity Candidate Nimacimab | SKYE Stock News - GuruFocus

05:15 AM

05:11 AM

Skye Bioscience Partners with Arecor Therapeutics to Enhance Nimacimab Formulation for Obesity Treatment - Nasdaq

05:11 AM

05:02 AM

Skye Bioscience Establishes Partnership with Arecor - GlobeNewswire

05:02 AM

05:00 AM

New Obesity Drug Breakthrough: Skye Bioscience's Once-Weekly Treatment Gets Powerful Upgrade - Stock Titan

05:00 AM

May 18, 2025

Ensign Peak Advisors Inc Sells 132,713 Shares of Skye Bioscience, Inc. (NASDAQ:SKYE) - MarketBeat

May 18, 2025

May 17, 2025

Skye Bioscience, Inc. (NASDAQ:SKYE) Receives Average Rating of "Buy" from Brokerages - MarketBeat

May 17, 2025

May 15, 2025

Skye Bioscience (NASDAQ:SKYE) Posts Quarterly Earnings Results, Beats Expectations By $0.03 EPS - MarketBeat

May 15, 2025

May 14, 2025

Skye Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire

May 14, 2025

Skye Bioscience, Inc. (NASDAQ:SKYE) Receives Consensus Rating of “Buy” from Analysts - Defense World

May 14, 2025

Skye Bioscience, Inc. (NASDAQ:SKYE) Receives $16.60 Consensus PT from Analysts - Defense World

May 14, 2025

Brokerages Set Skye Bioscience, Inc. (NASDAQ:SKYE) Target Price at $16.60 - Defense World

May 14, 2025

May 13, 2025

Skye Bioscience Awards 100,000 Share Options at $1.82 with 4-Year Vesting Terms - Stock Titan

May 13, 2025

Skye Bioscience (SKYE) Reveals Key Findings on CB1 Inhibitors an - GuruFocus

May 13, 2025

Skye Bioscience Clinical Model Demonstrating Necessity of - GlobeNewswire

May 13, 2025

Skye Bioscience Clinical Model Demonstrating Necessity of Peripheral CB1 Inhibition for Weight Loss Presented at European Congress on Obesity - Stock Titan

May 13, 2025

Skye Bioscience, Inc. (NASDAQ:SKYE) Shares Bought by Barclays PLC - Defense World

May 13, 2025

Barclays PLC Has $198,000 Stock Position in Skye Bioscience, Inc. (NASDAQ:SKYE) - Defense World

May 13, 2025

May 12, 2025

Skye Bioscience (SKYE) Receives Adjusted Price Target from Oppen - GuruFocus

May 12, 2025

Oppenheimer cuts Skye Bioscience price target to $17 By Investing.com - Investing.com South Africa

May 12, 2025

Oppenheimer cuts Skye Bioscience price target to $17 - Investing.com

May 12, 2025

Braidwell LP Invests $2.34 Million in Skye Bioscience, Inc. (NASDAQ:SKYE) - MarketBeat

May 12, 2025

May 10, 2025

Levi & Korsinsky Investigates Possible Securities Fraud Violations by Skye Bioscience, Inc. (SKYE) - ACCESS Newswire

May 10, 2025

May 09, 2025

Earnings call transcript: Skye Bioscience Reports Q1 2025 Financials Amid R&D Expansion - Investing.com Nigeria

May 09, 2025

Skye Bioscience, Inc. 2025 Q1ResultsEarnings Call Presentation (NASDAQ:SKYE) - Seeking Alpha

May 09, 2025